China is also striving to streamline diabetes treatment. One
initiative I find particularly impressive is the standardised care
model developed by the National Metabolic Disease Management Center,
which has already been rolled out to around 600 hospitals. The medical
data generated by this system allow for dynamic, big-data analyses of
diabetes epidemiology, prevention, diagnosis and treatment – and can
even be linked to large-scale clinical trial programmes.
We're also working closely with the Chinese government to
strengthen the healthcare system and build capacity by training
doctors in hospitals and primary care centres. Furthermore, in our
research centre in Beijing, our scientists are reaching out to
Chinese biotech start-ups and incubators.
However, we also know that unless China improves prevention, the
burden of diabetes could become unsustainable. So it's significant
that six Chinese cities – Beijing, Tianjin, Shanghai, Hangzhou, Xiamen
and Chongqing – have joined our Cities Changing Diabete partnership,
addressing the social and cultural factors linked to urban living that
can increase the risk of type 2 diabetes. With 80% of Chinese people
expected to be living in cities by 2050, up from just 20% in 1980, the
need for action is urgent – and our role in developing innovative
solutions for patients has never been more important.
For more information, contact Chris Moss,